Notice: Function _load_textdomain_just_in_time was called incorrectly. Translation loading for the wordpress-seo domain was triggered too early. This is usually an indicator for some code in the plugin or theme running too early. Translations should be loaded at the init action or later. Please see Debugging in WordPress for more information. (This message was added in version 6.7.0.) in /var/www/html/wp-includes/functions.php on line 6260 Millennium, J&JPRD Begin More Velcade Studies | Contract Pharma

What are you searching for?

Sign in
Breaking News, Trials & Filings

Millennium, J&JPRD Begin More Velcade Studies

Author Image

By: Tim Wright

Editor-in-Chief, Contract Pharma

Millennium Pharmaceuticals and co-development partner Johnson & Johnson Pharmaceutical Research & Development, L.L.C. (J&JPRD) have initiated a three-arm, randomized, Phase II study of Velcade and pemetrexed in patients with locally advanced or metastatic non-small cell lung cancer (NSCLC) who have failed prior chemotherapy treatment. The study will assess the potential benefits of combining the activity of two targeted therapies with different mechanisms of action. Also underway is a two-arm, randomized, Phase II study of Velcade in combination with erlotinib for patients with locally advanced or metastatic NSCLC and a study of single-agent Velcade in relapsed bronchioalveolar carcinoma and adenocarcinoma of the lung. In newly diagnosed patients with NSCLC, a study to evaluate Velcade in combination with other agents has recently been completed.

The Phase II randomized, open-label, multi-center study will enroll approximately 135 patients. The primary endpoint is objective response rate as assessed by Response Evaluation Criteria in Solid Tumors (RECIST) criteria. Secondary endpoints of the study include disease control rates, time to progression, progression-free survival and safety. Patients will be assigned to one of three treatment groups: Velcade in combination with pemetrexed, pemetrexed alone or Velcade alone.

Add us as a preferred source on Google

Get the latest Contract Pharma news, insights and analysis in your Google Search and AI experiences.

Add Contract Pharma as a preferred source on Google (opens in a new tab)

Keep Up With Our Content. Subscribe To Contract Pharma Newsletters